Date: 2014-01-07
Type of information: Resignation
Compound:
Company: Bind Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: resignation
Action mechanism:
Disease:
Details: * On April 2, 2013, Bind Therapeutics announced the appointment of Gregory I. Berk, M.D. as Chief Medical Officer, effective immediately. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Berk is an oncology veteran with more than 20 years of industry and academic experience. Prior to joining Bind, Dr. Berk served as Chief Medical Officer of Intellikine, a clinical stage company developing small molecule drugs targeting signal transduction networks, which was acquired by Takeda Pharmaceutical. Dr. Berk was previously Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the company's overall clinical strategy, including efforts to expand the indications for Abraxane®, as well as oversee the clinical development of their entire pipeline. Dr. Berk also served on the integration leadership team during the Celgene acquisition of Abraxis in 2010. Dr. Berk obtained his medical degree from Case Western Reserve University, and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology, at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time Dr. Berk served as an investigator on several industry-sponsored and cooperative group clinical trials, including the pivotal trials for Gleevec® and Avastin®.
Financial terms:
Latest news: * On January 7, 2014, Bind Therapeutics announced that Greg Berk, M.D., Chief Medical Officer, will be leaving Bind to pursue another opportunity. Dr. Berk will serve as an advisor to BIND after his departure. The Company is initiating a search for a new chief medical officer. Edward Schnipper, M.D., who has been serving as an advisor to BIND and formerly served as BIND's chief medical officer, will serve as the company's chief medical officer on an interim basis.
